California-based research and development company. Alliance has several patents regarding 'microbubble' compositions such as Imagent® that are intended to enhance ultrasound imaging and Imagent GI as a gastrointestinal MRI contrast agent. Another product is Oxygent™, a synthetic 'blood substitute'.

MRI Contrast Agents:

• Imagent GI

The testing on software performed by the developers, usually during the development process; also, the first of several stages in the software testing process (see beta test).

From Hitachi Medical Systems America, Inc.;
the AIRIS made its debut in 1995. Hitachi followed up with the AIRIS II system, which has proven equally successfully. 'All told, Hitachi has installed more than 1,000 MRI systems in the U.S., holding more than 17 percent of the total U.S. MRI installed base, and more than half of the installed base of open MR systems,' says Antonio Garcia, Frost and Sullivan industry research analyst. Now Altaire employs a blend of innovative Hitachi features called VOSIâ„¢ technology, optimizing each sub-system's performance in concert with the other sub-systems, to give the seamless mix of high-field performance and the patient comfort, especially for claustrophobic patients, of open MR systems.

A current that continuously changes in magnitude and direction. Commonly the current changes at a frequency of 50 - 60 Hz.

The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

MRI Contrast Agents: